AMAG Pharmaceuticals (AMAG) Shares Fall Nearly 7%

Shares of AMAG Pharmaceuticals, Inc. (Nasdaq: AMAG) tumbled 6% during morning trading after the company produced financial results that failed to impress Wall Street.

The bio-pharmaceutical company reported a net loss of $18.4 million, or $1.07 per share, versus a net loss of $21.8 million, or $1.28 per share, for the same quarter a year earlier.

Revenue climbed from $0.6 million a year earlier, to the latest quarter's $13.1 million. The huge increase in revenue was due to the approval and release of AMAG Pharmaceuticals' Feraheme last year.